All results
27 results for weight and metabolic health study
-
NIH AIM 2 - Low Dose Pioglitazone in NASH
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic…
- Ages
- 21 Years - 75 Years
- Sexes
- All
-
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors (NOURISH-T+)
Pediatric cancer survivors are at an increased risk of excessive weight gain and reduced exercise behaviors with the potential for this risk to worsen over…
- Ages
- 5 Years - 14 Years
- Sexes
- All
-
ORIF vs. THA for FNF
The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult…
- Ages
- 60 Years - N/A
- Sexes
- All
-
OxyAging
Some research suggests that administration of oxytocin with oxycodone may reduce its abuse liability and improve its ability to reduce pain. In a 6-session…
- Ages
- 45 Years - 85 Years
- Sexes
- All
-
PK sensitivity in fluticasone propionate dry powder inhalers
When a drug company first develops a drug, the company has to show the Food and Drug Administration (FDA) that the drug is safe and effective. If FDA concludes…
- Ages
- 18 Years - 50 Years
- Sexes
- All
-
PPMI Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI)
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical…
- Ages
- 30 Years - N/A
- Sexes
- All
-
PSSG
The purpose of this study is to examine the treatment, both surgical and non-surgical, of patients with any form of early onset scoliosis. Such treatment may…
- Ages
- 1 Day - 18 Years
- Sexes
- All
-
Phase I/II Study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patie
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy,…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or…
- Ages
- 75 Years - N/A
- Sexes
- All
-
Protocol TN-25
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr…
- Ages
- 8 Years - 45 Years
- Sexes
- All